UPDATE 1-Biogen 1st qtr results disappoint Wall Street as Tecfidera sales slow

April 24 (Reuters) - Biogen Inc posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis (MS) drug Tecfidera showed signs of slowing growth, sending the company's shares down 3 percent in premarket trading on Friday.